Selected article for: "viral entry and wide array"

Author: Trbojević-Akmačić, Irena; Petrović, Tea; Lauc, Gordan
Title: SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection
  • Cord-id: n76wr1qg
  • Document date: 2021_9_20
  • ID: n76wr1qg
    Snippet: The severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection displays a wide array of clinical manifestations. Although some risk factors for coronavirus disease 2019 (COVID-19) severity and outcomes have been identified the underlying biologic mechanisms are still not well understood. The surface SARS-CoV-2 proteins are heavily glycosylated enabling host cell interaction and viral entry. Angiotensin-converting enzyme 2 (ACE2) has been identified to be the main host cell re
    Document: The severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection displays a wide array of clinical manifestations. Although some risk factors for coronavirus disease 2019 (COVID-19) severity and outcomes have been identified the underlying biologic mechanisms are still not well understood. The surface SARS-CoV-2 proteins are heavily glycosylated enabling host cell interaction and viral entry. Angiotensin-converting enzyme 2 (ACE2) has been identified to be the main host cell receptor enabling SARS-CoV-2 cell entry after interaction with its S glycoprotein. However, recent studies report SARS-CoV-2 S glycoprotein interaction with other cell receptors, mainly C-type lectins which recognize specific glycan epitopes facilitating SARS-CoV-2 entry to susceptible cells. Here, we are summarizing the main findings on SARS-CoV-2 interactions with ACE2 and other cell membrane surface receptors and soluble lectins involved in the viral cell entry modulating its infectivity and potentially playing a role in subsequent clinical manifestations of COVID-19. [Image: see text]

    Search related documents:
    Co phrase search for related documents
    • low density and lung inflammation: 1
    • low density and lung injury: 1, 2, 3, 4, 5
    • low density and lung tissue: 1, 2, 3, 4, 5, 6, 7
    • low density and lymph node: 1, 2
    • low density and macrophage monocyte: 1, 2
    • low expression and lung immune cell: 1
    • low expression and lung inflammation: 1, 2, 3, 4, 5
    • low expression and lung injury: 1, 2, 3, 4
    • low expression and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • low expression and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • lung injury and lymph hepatic: 1
    • lung injury and lymph node: 1
    • lung injury and lymphatic tissue: 1
    • lung injury and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • lung tissue and lymph hepatic: 1
    • lung tissue and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • lung tissue and lymphatic tissue: 1, 2
    • lung tissue and macrophage dc: 1
    • lung tissue and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9